Emanuela Felley-Bosco

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


84 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1987 |
 
Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
Wu L., Dell'Anno I., Lapidot M., Sekido Y., Chan M.L., Kohno M., Serre-Beinier V., Felley-Bosco E., de Perrot M., 2019/01. Lung cancer, 127 pp. 138-145. Peer-reviewed.
 
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.
Tallón de Lara P., Cecconi V., Hiltbrunner S., Yagita H., Friess M., Bode B., Opitz I., Vrugt B., Weder W., Stolzmann P. et al., 2018/12/15. Clinical cancer research, 24 (24) pp. 6345-6354. Peer-reviewed.
 
Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection
Bachas Costa, Hodzic Jasmina, van der Mijn Johannes C., Stoepker Chantal, Verheul Henk M. W., Wolthuis Rob M. F., Felley-Bosco Emanuela, van Wieringen Wessel N., van Beusechem Victor W., Brakenhoff Ruud H. et al., 2018/12. BMC Bioinformatics, 19 (1) pp. 1-10.
 
Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions.
Felley-Bosco E., 2018/11/12. International journal of molecular sciences, 19 (11). Peer-reviewed.
 
Asbestos: Modern Insights for Toxicology in the Era of Engineered Nanomaterials.
Felley-Bosco E., MacFarlane M., 2018/10/15. Chemical research in toxicology, 31 (10) pp. 994-1008. Peer-reviewed.
 
How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations.
Rehrauer H., Wu L., Blum W., Pecze L., Henzi T., Serre-Beinier V., Aquino C., Vrugt B., de Perrot M., Schwaller B. et al., 2018/05. Oncogene, 37 (20) pp. 2645-2659. Peer-reviewed.
 
Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.
Wu L., Blum W., Zhu C.Q., Yun Z., Pecze L., Kohno M., Chan M.L., Zhao Y., Felley-Bosco E., Schwaller B. et al., 2018/04/27. BMC cancer, 18 (1) p. 471. Peer-reviewed.
 
Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells.
Kresoja-Rakic J., Felley-Bosco E., 2018/04/25. Journal of visualized experiments 134 p. 134. Peer-reviewed.
 
Non-Coding Transcript Heterogeneity in Mesothelioma: Insights from Asbestos-Exposed Mice.
Felley-Bosco E., Rehrauer H., 2018/04/11. International journal of molecular sciences, 19 (4) pp. E1163. Peer-reviewed.
 
The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
Schürch Christian M., Forster Stefan, Brühl Frido, Yang Sara H., Felley-Bosco Emanuela, Hewer Ekkehard, 2018/01/02. OncoImmunology, 7 (1) pp. e1373235.
 
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.
Oehl K., Kresoja-Rakic J., Opitz I., Vrugt B., Weder W., Stahel R., Wild P., Felley-Bosco E., 2018. Frontiers in oncology, 8 p. 40. Peer-reviewed.
 
Mesothelioma Heterogeneity: Potential Mechanisms
Felley-Bosco Emanuela, 2018., MDPI.
A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.
Parrotta R., Okonska A., Ronner M., Weder W., Stahel R., Penengo L., Felley-Bosco E., 2017/04/04. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer pp. 1-14. Peer-reviewed.
Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells
Blum Walter, Pecze László, Felley-Bosco Emanuela, Wu Licun, de Perrot Marc, Schwaller Beat, 2017/03. Stem Cell Reports pp. 73-97. Peer-reviewed.
 
Long Noncoding RNAs in Cancer and Therapeutic Potential.
Renganathan A., Felley-Bosco E., 2017. Advances in Experimental Medicine and Biology, 1008 pp. 199-222. Peer-reviewed.
Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.
Kresoja-Rakic J., Sulemani M., Kirschner M.B., Ronner M., Reid G., Kao S., Schwaller B., Weder W., Stahel R.A., Felley-Bosco E., 2017. Frontiers in Genetics, 8 p. 70. Peer-reviewed.
 
Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma
Meerang Mayura, Bérard Karima, Friess Martina, Bitanihirwe Byron K.Y., Soltermann Alex, Vrugt Bart, Felley-Bosco Emanuela, Bueno Raphael, Richards William G., Seifert Burkhardt et al., 2016/10. Molecular Oncology, 10 (8) pp. 1255-1265. Peer-reviewed.
 
Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
Meerang M., Bérard K., Felley-Bosco E., Lauk O., Vrugt B., Boss A., Kenkel D., Broggini-Tenzer A., Stahel R.A., Arni S. et al., 2016. Molecular Cancer Therapeutics pp. 1095-105. Peer-reviewed.
Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.
Kresoja-Rakic J., Kapaklikaya E., Ziltener G., Dalcher D., Santoro R., Christensen B.C., Johnson K.C., Schwaller B., Weder W., Stahel R.A. et al., 2016. Oncotarget, 7 (16) pp. 21272-21286. Peer-reviewed.
 
Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.
Barbone D., Follo C., Echeverry N., Gerbaudo V.H., Klabatsa A., Bueno R., Felley-Bosco E., Broaddus V.C., 2015. PLoS One, 10 (8) pp. e0134825. Peer-reviewed.
 
Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.
Blum W., Pecze L., Felley-Bosco E., Worthmüller-Rodriguez J., Wu L., Vrugt B., de Perrot M., Schwaller B., 2015. In Vitro Cellular and Developmental Biology. Animal, 51 (7) pp. 714-721. Peer-reviewed.
 
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Thies S., Friess M., Frischknecht L., Korol D., Felley-Bosco E., Stahel R., Vrugt B., Weder W., Opitz I., Soltermann A., 2015. PLoS One, 10 (9) pp. e0139312. Peer-reviewed.
 
Hedgehog Signaling in Malignant Pleural Mesothelioma.
Felley-Bosco E., Opitz I., Meerang M., 2015. Genes, 6 (3) pp. 500-511. Peer-reviewed.
 
Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.
Echeverry N., Ziltener G., Barbone D., Weder W., Stahel R.A., Broaddus V.C., Felley-Bosco E., 2015. Cell Death and Disease, 6 (5) pp. e1757. Peer-reviewed.
 
Overexpression or absence of calretinin in mouse primary mesothelial cells inversely affects proliferation and cell migration.
Blum W., Pecze L., Felley-Bosco E., Schwaller B., 2015. Respiratory Research, 16 (1) p. 153. Peer-reviewed.
 
Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Rusch A., Ziltener G., Nackaerts K., Weder W., Stahel R.A., Felley-Bosco E., 2015. Lung Cancer, 87 (1) pp. 77-79. Peer-reviewed.
Searching for targets for the systemic therapy of mesothelioma.
Stahel R.A., Weder W., Felley-Bosco E., Petrausch U., Curioni-Fontecedro A., Schmitt-Opitz I., Peters S., 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 26 (8) pp. 1649-1660. Peer-reviewed.
 
CD74: a new prognostic factor for patients with malignant pleural mesothelioma.
Otterstrom C., Soltermann A., Opitz I., Felley-Bosco E., Weder W., Stahel R.A., Triponez F., Robert J.H., Serre-Beinier V., 2014. British Journal of Cancer, 110 (8) pp. 2040-2046. Peer-reviewed.
GAS5 long non-coding RNA in malignant pleural mesothelioma.
Renganathan A., Kresoja-Rakic J., Echeverry N., Ziltener G., Vrugt B., Opitz I., Stahel R.A., Felley-Bosco E., 2014. Molecular Cancer, 13 (1) p. 119. Peer-reviewed.
 
Hippo/YAP pathway for targeted therapy.
Felley-Bosco E., Stahel R., 2014. Translational Lung Cancer Research, 3 (2) pp. 75-83. Peer-reviewed.
 
PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
Bitanihirwe B.K., Meerang M., Friess M., Soltermann A., Frischknecht L., Thies S., Felley-Bosco E., Tsao M.S., Allo G., de Perrot M. et al., 2014. Journal of Thoracic Oncology, 9 (2) pp. 239-247. Peer-reviewed.
 
Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress.
Kotov I.N., Siebring-van Olst E., Knobel P.A., van der Meulen-Muileman I.H., Felley-Bosco E., van Beusechem V.W., Smit E.F., Stahel R.A., Marti T.M., 2014. Molecular Oncology, 8 (8) pp. 1747-1759.
 
Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.
Cerciello F., Choi M., Nicastri A., Bausch-Fluck D., Ziegler A., Vitek O., Felley-Bosco E., Stahel R., Aebersold R., Wollscheid B., 2013. Clinical Proteomics, 10 (1) p. 16. Peer-reviewed.
 
Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy.
Shi Y., Felley-Bosco E., Marti T.M., Stahel R.A., 2012. PLoS One, 7 (9) pp. e45354. Peer-reviewed.
 
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Fischer B., Frei C., Moura U., Stahel R., Felley-Bosco E., 2012. Lung Cancer, 78 (1) pp. 23-29.
 
Proteomic surfaceome analysis of mesothelioma.
Ziegler A., Cerciello F., Bigosch C., Bausch-Fluck D., Felley-Bosco E., Ossola R., Soltermann A., Stahel R.A., Wollscheid B., 2012. Lung Cancer, 75 (2) pp. 189-196.
 
Role of hedgehog signaling in malignant pleural mesothelioma.
Shi Y., Moura U., Opitz I., Soltermann A., Rehrauer H., Thies S., Weder W., Stahel R.A., Felley-Bosco E., 2012. Clinical Cancer Research, 18 (17) pp. 4646-4656. Peer-reviewed.
 
Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.
Shi Y., Felley-Bosco E., Marti T.M., Orlowski K., Pruschy M., Stahel R.A., 2012. BMC Cancer, 12 (1) p. 571.
 
Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model.
Shi Y., Hollenstein A., Felley-Bosco E., Fraefel C., Ackermann M., Soltermann A., Weder W., Stahel R., Pruschy M., Opitz I., 2011. Lung Cancer, 71 (3) pp. 370-371.
 
Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.
Sidi R., Pasello G., Opitz I., Soltermann A., Tutic M., Rehrauer H., Weder W., Stahel R.A., Felley-Bosco E., 2011. European Journal of Cancer, 47 (2) pp. 326-332. Peer-reviewed.
 
Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells.
Knobel P.A., Kotov I.N., Felley-Bosco E., Stahel R.A., Marti T.M., 2011. Neoplasia, 13 (10) pp. 961-970.
 
Pleural mesothelioma side populations have a precursor phenotype.
Frei C., Opitz I., Soltermann A., Fischer B., Moura U., Rehrauer H., Weder W., Stahel R., Felley-Bosco E., 2011. Carcinogenesis, 32 (9) pp. 1324-1332. Peer-reviewed.
 
Functional inactivation of NF2/merlin in human mesothelioma.
Thurneysen C., Opitz I., Kurtz S., Weder W., Stahel R.A., Felley-Bosco E., 2009. Lung Cancer, 64 (2) pp. 140-147.
 
Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.
Ampollini L., Soltermann A., Felley-Bosco E., Lardinois D., Arni S., Speck R.F., Weder W., Opitz I., 2009. European Journal of Cardio-thoracic Surgery, 35 (3) pp. 457-462. Peer-reviewed.
 
Malignant pleural mesothelioma.
Stahel R.A., Felley-Bosco E., Opitz I., Weder W., 2009. Future Oncology, 5 (3) pp. 391-402.
 
Eléments de toxicologie spéciale et professionnelle
Diezi Jacques, Boillat Marcel-André, 2008. pp. 21-52 dans Diezi Jacques, Felley-Bosco Emanuela (eds.) Précis de toxicologie, Médecine & Hygiène.
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
Belyanskaya L.L., Marti T.M., Hopkins-Donaldson S., Kurtz S., Felley-Bosco E., Stahel R.A., 2007. Molecular Cancer, 6 p. 66.
 
Src-mediated phosphorylation regulates subcellular distribution and activity of human inducible nitric oxide synthase.
Hausel P., Latado H., Courjault-Gautier F., Felley-Bosco E., 2006. Oncogene, 25 (2) pp. 198-206.
 
Structural and functional properties of two human FXYD3 (Mat-8) isoforms.
Bibert S., Roy S., Schaer D., Felley-Bosco E., Geering K., 2006. Journal of Biological Chemistry, 281 (51) pp. 39142-39151. Peer-reviewed.
 
Inducible nitric oxide synthase-dependent stimulation of PKGI and phosphorylation of VASP in human embryonic kidney cells.
André M., Latado H., Felley-Bosco E., 2005. Biochemical Pharmacology, 69 (4) pp. 595-602.
 
Polarized distribution of inducible nitric oxide synthase regulates activity in intestinal epithelial cells.
Rumbo M., Courjault-Gautier F., Sierro F., Sirard J.C., Felley-Bosco E., 2005. FEBS Journal, 272 (2) pp. 444-453.
 
Proteomics and chronic inflammatory bowel diseases.
Felley-Bosco E., André M., 2004. Pathology, Research and Practice, 200 (2) pp. 129-133.
 
Heme oxygenase-1 induction by endogenous nitric oxide: influence of intracellular glutathione.
André M., Felley-Bosco E., 2003. FEBS Letters, 546 (2-3) pp. 223-227.
 
Postanoxic functional recovery of the developing heart is slightly altered by endogenous or exogenous nitric oxide.
Terrand J., Felley-Bosco E., Courjault-Gautier F., Rochat A.C., Kucera P., Raddatz E., 2003. Molecular and Cellular Biochemistry, 252 (1-2) pp. 53-63. Peer-reviewed.
 
Caveolin-1-mediated post-transcriptional regulation of inducible nitric oxide synthase in human colon carcinoma cells.
Felley-Bosco E., Bender F., Quest A.F., 2002. Biological Research, 35 (2) pp. 169-176.
 
Oxidative stress in gastric mucosa of asymptomatic humans infected with Helicobacter pylori: effect of bacterial eradication.
Felley C.P., Pignatelli B., Van Melle G.D., Crabtree J.E., Stolte M., Diezi J., Corthesy-Theulaz I., Michetti P., Bancel B., Patricot L.M. et al., 2002. Helicobacter, 7 (6) pp. 342-348. Peer-reviewed.
 
Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases.
Barceló-Batllori S., André M., Servis C., Lévy N., Takikawa O., Michetti P., Reymond M., Felley-Bosco E., 2002. Proteomics, 2 (5) pp. 551-60. Peer-reviewed.
 
L-tyrosine and nitric oxide synergize to prevent cytotoxic effects of superoxide.
Souici A.C., Fitzhugh A.L., Keefer L.K., Felley-Bosco E., 2001. Toxicology, 165 (2-3) pp. 163-170.
 
Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells.
Felley-Bosco E., Bender F.C., Courjault-Gautier F., Bron C., Quest A.F., 2000. Proceedings of the National Academy of Sciences of the United States of America, 97 (26) pp. 14334-14339.
 
Dominant negative MyD88 proteins inhibit interleukin-1beta /interferon-gamma -mediated induction of nuclear factor kappa B-dependent nitrite production and apoptosis in beta cells.
Dupraz P., Cottet S., Hamburger F., Dolci W., Felley-Bosco E., Thorens B., 2000. Journal of Biological Chemistry, 275 (48) pp. 37672-37678.
 
Transition mutation in codon 248 of the p53 tumor suppressor gene induced by reactive oxygen species and a nitric oxide-releasing compound.
Souici A.C., Mirkovitch J., Hausel P., Keefer L.K., Felley-Bosco E., 2000. Carcinogenesis, 21 (2) pp. 281-287. Peer-reviewed.
 
Expression of the inducible NO synthase in human monocytic U937 cells allows high output nitric oxide production.
Bertholet S., Tzeng E., Felley-Bosco E., Mauël J., 1999. Journal of Leukocyte Biology, 65 (1) pp. 50-58.
 
Information transfer between large and small two-dimensional polyacrylamide gel electrophoresis.
Felley-Bosco E., Demalte I., Barcelo S., Sanchez J.C., Hochstrasser D.F., Schlegel W., Reymond M.A., 1999. Electrophoresis, 20 (18) pp. 3508-3513. Peer-reviewed.
Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer.
Ambs S., Bennett W.P., Merriam W.G., Ogunfusika M.O., Oser S.M., Harrington A.M., Shields P.G., Felley-Bosco E., Hussain S.P., Harris C.C., 1999. Journal of the National Cancer Institute, 91 (1) pp. 86-88. Peer-reviewed.
 
RESPONSE: Re: Relationship Between p53 Mutations and Inducible Nitric Oxide Synthase Expression in Human Colorectal Cancer.
Ambs S., Harris C.C., 1999. Journal of the National Cancer Institute, 91 (17) pp. 1510-1511.
 
The nitric oxide pathway in pig isolated calyceal smooth muscle.
Iselin C.E., Ny L., Mastrangelo D., Felley-Bosco E., Larsson B., Alm P., Andersson K.E., 1999. Neurourology and Urodynamics, 18 (6) pp. 673-685. Peer-reviewed.
 
Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression.
Ambs S., Merriam W.G., Bennett W.P., Felley-Bosco E., Ogunfusika M.O., Oser S.M., Klein S., Shields P.G., Billiar T.R., Harris C.C., 1998. Cancer Research, 58 (2) pp. 334-341. Peer-reviewed.
 
Nitric oxide, altered DNA, and mammalian disease.
Felley-Bosco E., Buzard G.S., Billiar T.R., Keefer L.K., 1998. pp. 287-325 dans Aruoma O.I., Halliwell B. (eds.) Molecular biology of free radicals in human diseases, Oica International.
 
Role of nitric oxide in genotoxicity: implication for carcinogenesis.
Felley-Bosco E., 1998. Cancer Metastasis Reviews, 17 (1) pp. 25-37.
Decreased activity of inducible nitric oxide synthase type 2 and modulation of the expression of glutathione S-transferase alpha, bcl-2, and metallothioneins during the differentiation of CaCo-2 cells.
Vecchini F., Pringault E., Billiar T.R., Geller D.A., Hausel P., Felley-Bosco E., 1997. Cell Growth and Differentiation, 8 (2) pp. 261-268. Peer-reviewed.
 
Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53.
Forrester K., Ambs S., Lupold S.E., Kapust R.B., Spillare E.A., Weinberg W.C., Felley-Bosco E., Wang X.W., Geller D.A., Tzeng E. et al., 1996. Proceedings of the National Academy of Sciences of the United States of America, 93 (6) pp. 2442-2447. Peer-reviewed.
 
Involvement of a transforming-growth-factor-beta-like molecule in tumor-cell-derived inhibition of nitric-oxide synthesis in cerebral endothelial cells.
Murata J., Corradin S.B., Felley-Bosco E., Juillerat-Jeanneret L., 1995. International Journal of Cancer, 62 (6) pp. 743-748.
 
Nitric oxide and ethylnitrosourea: relative mutagenicity in the p53 tumor suppressor and hypoxanthine-phosphoribosyltransferase genes.
Felley-Bosco E., Mirkovitch J., Ambs S., Macé K., Pfeifer A., Keefer L.K., Harris C.C., 1995. Carcinogenesis, 16 (9) pp. 2069-2074.
 
Species specificity at the molecular level: the case of nitric oxide synthases.
Felley-Bosco E., 1995. Archives of Toxicology. Supplement, 17 pp. 357-366.
 
Constitutive expression of inducible nitric oxide synthase in human bronchial epithelial cells induces c-fos and stimulates the cGMP pathway.
Felley-Bosco E., Ambs S., Lowenstein C.J., Keefer L.K., Harris C.C., 1994. American Journal of Respiratory Cell and Molecular Biology, 11 (2) pp. 159-164.
Functional studies of a germ-line polymorphism at codon 47 within the p53 gene.
Felley-Bosco E., Weston A., Cawley H.M., Bennett W.P., Harris C.C., 1993. American Journal of Human Genetics, 53 (3) pp. 752-759.
 
Dietary calcium restriction enhances cadmium-induced metallothionein synthesis in rats.
Felley-Bosco E., Diezi J., 1992. Toxicology Letters, 60 (2) pp. 139-144. Peer-reviewed.
A genotypic mutation system measuring mutations in restriction recognition sequences.
Felley-Bosco E., Pourzand C., Zijlstra J., Amstad P., Cerutti P., 1991. Nucleic Acids Research, 19 (11) pp. 2913-2919. Peer-reviewed.
 
Cadmium uptake and induction of metallothionein synthesis in a renal epithelial cell line (LLC-PK1).
Felley-Bosco E., Diezi J., 1991. Archives of Toxicology, 65 (2) pp. 160-163. Peer-reviewed.
 
A mammalian mutation system avoiding phenotypic selection: the RFLP/PCR approach.
Zijlstra J., Felley-Bosco E., Amstad P., Cerutti P., 1990. Progress in Clinical and Biological Research, 347 pp. 187-200. Peer-reviewed.
 
Isoelectric focusing of urinary metallothionein.
Felley-Bosco E., Hunziker P.E., Savolainen H., 1990. Scandinavian Journal of Clinical and Laboratory Investigation, 50 (3) pp. 343-346. Peer-reviewed.
 
Thermodynamics of oxygen binding to arctic hemoglobins. The case of reindeer.
Giardina B., Condò S.G., Petruzzelli R., Bardgard A., Brix O., 1990. Biophysical Chemistry, 37 (1-3) pp. 281-286. Peer-reviewed.
 
Fate of cadmium in rat renal tubules: a micropuncture study.
Felley-Bosco E., Diezi J., 1989. Toxicology and Applied Pharmacology, 98 (2) pp. 243-251. Peer-reviewed.
 
Fate of cadmium in rat renal tubules: a microinjection study.
Felley-Bosco E., Diezi J., 1987. Toxicology and Applied Pharmacology, 91 (2) pp. 204-211. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University